A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes between the age of 18 and 44 years old, who are not taking any medications

1. To assess the effect of treatment with MK-3102 compared with placebo on A1C. 2. To assess the safety and tolerability of MK-3102.